Establishment Labs, a Costa Rica-based medical technology company, has launched Preservé, a breast tissue preserving technology, in Brazil.
Preservé is designed to preserve breast tissue during aesthetic surgery, ensuring more stable and natural outcomes compared to traditional breast augmentation. It helps maintain the structural anatomy and function of the breast.
It uses Establishment Labs’ proprietary minimally invasive surgical tools and Ergonomix2 implants.
These implants feature the patented SmoothSilk surface for enhanced biocompatibility and softness. Their unique shape adapts as the body changes position.
Preservé is ideal for primary augmentations up to four cups, hybrid augmentations, and mastopexy augmentations.
This marks the first step in its global rollout. Preservé is the second product in the company’s minimally invasive platform.
It builds on technologies developed with Mia Femtech, Establishment Labs’ minimally invasive experience for breast harmonisation.
Establishment Labs founder and CEO Juan José Chacón-Quirós said: “Whereas Mia made minimally invasive breast aesthetics possible for women looking for a one to two cup enhancement, Preservé allows less invasive breast surgery for the day-to-day breast augmentation patient.
“Historically, many women have not been convinced by traditional methods and legacy techniques.
“With Mia and Preservé, we have solutions that address these concerns. The technology platform of breast tissue preservation allows plastic surgeons to create natural results with less disruption of the patient’s breast tissue.”
Preservé was commercially launched last weekend at the Brazilian Breast Meeting in Rio de Janeiro.
Additional global launches of Preservé are planned for later this year.
Currently, the medical devices used in Preservé are not approved for commercial distribution in the US.
Nasdaq-listed Establishment Labs is focused on improving women’s health through new solutions in breast aesthetics and reconstruction.
With over four million Motiva devices delivered, the company offers products like the Motiva Flora tissue expander, Mia Femtech, Preservé, GEM, and Zensor. These devices set new standards for safety, patient satisfaction, and minimally invasive procedures.
In September 2024, the breast aesthetics company secured approval from the US Food and Drug Administration (FDA) for the use of Motiva SmoothSilk Ergonomix and Motiva SmoothSilk Round breast implants in primary and revision breast augmentation.
